Trastuzumab Cardiac Side Effects: Only Time Will Tell
- 1 November 2005
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (31) , 7775-7776
- https://doi.org/10.1200/jco.2005.04.1558
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31Journal of Clinical Oncology, 2005
- The Use of Radiotherapy After Mastectomy: A Review of the LiteratureJournal of Clinical Oncology, 2005
- Prognostic factors affecting the natural history of node-negative breast cancerBreast Cancer Research and Treatment, 2005
- Neuregulin Receptor ErbB2 Localization at T-tubule in Cardiac and Skeletal MuscleJournal of Histochemistry & Cytochemistry, 2005
- The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast CancerJournal of Clinical Oncology, 2004
- Essential Roles of Her2/erbB2 in Cardiac Development and FunctionRecent Progress in Hormone Research, 2004
- ErbB2 Pathways in Heart and Neural DiseasesTrends in Cardiovascular Medicine, 2003
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001